@article{discovery10186762,
            note = {{\copyright} 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
This is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBYNC-ND), where it is permissible to download and share the work provided it
is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.},
       publisher = {Ovid Technologies (Wolters Kluwer Health)},
            year = {2024},
           month = {February},
         journal = {The Pediatric Infectious Disease Journal},
           title = {Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe},
             url = {http://dx.doi.org/10.1097/inf.0000000000004271},
          author = {Malik, Farihah and Crichton, Siobhan and Plotnikova, Yulia and Latysheva, Inga and Samarina, Anna and Pokorska-{\'S}piewak, Maria and Gomez, Marisa Navarro and Bailey, Heather and Thorne, Claire and Judd, Ali and Turkova, Anna and Collins, Intira Jeannie},
        abstract = {We evaluated the effectiveness and safety of direct-acting antivirals in adolescents with hepatitis C (HCV)/HIV coinfection using pooled individual patient-level data from 5 European cohorts. Of 122 participants in follow-up from November 2013 to August 2021, 19 were treated {\ensuremath{<}}18 years of age; of 15 with HCV RNA available at/after 12 weeks post-treatment, all had sustained virologic response with acceptable safety. This evidence addresses an important gap in knowledge of treatment outcomes in adolescents with HCV/HIV coinfection in real-life settings.},
        keywords = {Hepatitis C, HIV, treatment, adolescents, pediatric, directacting antivirals},
            issn = {0891-3668}
}